The number of physician-scientists and translational researchers working in lung cancer has not kept pace with the overall growth of the medical research community or with the growth in our basic knowledge base, resulting in an increasing number of unrealized basic and translational research opportunities. Yale is uniquely suited to helping rebuild this base with our strong commitment to basic and translational research. The Career Development Program (CDP) in the Yale SPORE in Lung Cancer (YSILC) has been designed to contribute substantively to ongoing efforts and new initiatives attempting to address this problem. Our translational research office at Yale (led by Dr. Herbst) has been committed to providing early seed funding and translational support to young investigators early in their research careers. The goal of the CDP is to educate a new generation of investigators committed to translational research in lung cancer. The CDP has substantial institutional commitment, both in terms of funding and infrastructure. Potential CDP candidates include promising junior faculty who are interested in establishing their career in translational lung cancer research or established investigators whose previous research has been in other areas. Junior faculty awardees will be paired with more established investigators in lung cancer research with a documented record of successful mentoring. In this way, the YSILC will stimulate the development of the next generation of physician scientists and translational researchers, addressing the most challenging issues in lung cancer research.

Public Health Relevance

PROGRAM NARRATIVE The Yale SPORE in Lung Cancer?s Career Development Program is a key program to foster the development of the next generation of physician-scientists in the area of human thoracic malignancies to faciliate diagnosis, prevention, and therapy of lung cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA196530-03
Application #
9325326
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2017-08-01
Budget End
2018-07-31
Support Year
3
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Yale University
Department
Type
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Zhang, Jinhua; Song, Kun; Wang, Jun et al. (2018) S100A4 blockage alleviates agonistic anti-CD137 antibody-induced liver pathology without disruption of antitumor immunity. Oncoimmunology 7:e1296996
Anastasiadou, Eleni; Faggioni, Alberto; Trivedi, Pankaj et al. (2018) The Nefarious Nexus of Noncoding RNAs in Cancer. Int J Mol Sci 19:
Toki, Maria I; Mani, Nikita; Smithy, James W et al. (2018) Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations. J Thorac Oncol 13:1884-1896
Park, Seyoung; Zhao, Hongyu (2018) Spectral clustering based on learning similarity matrix. Bioinformatics 34:2069-2076
Gettinger, S N; Choi, J; Mani, N et al. (2018) A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers. Nat Commun 9:3196
Adams, Brian D; Arem, Hannah; Hubal, Monica J et al. (2018) Exercise and weight loss interventions and miRNA expression in women with breast cancer. Breast Cancer Res Treat 170:55-67
Burslem, George M; Smith, Blake E; Lai, Ashton C et al. (2018) The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study. Cell Chem Biol 25:67-77.e3
Liu, Huafeng; Li, Xin; Hu, Li et al. (2018) A crucial role of the PD-1H coinhibitory receptor in suppressing experimental asthma. Cell Mol Immunol 15:838-845
Choe, Junho; Lin, Shuibin; Zhang, Wencai et al. (2018) mRNA circularization by METTL3-eIF3h enhances translation and promotes oncogenesis. Nature 561:556-560
Bade, Brett C; Hyer, J Madison; Bevill, Benjamin T et al. (2018) A Patient-Centered Activity Regimen Improves Participation in Physical Activity Interventions in Advanced-Stage Lung Cancer. Integr Cancer Ther 17:921-927

Showing the most recent 10 out of 74 publications